Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Ries

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Clinical & Translational Immunology|February 22, 2020
CD163<sup>+</sup> tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytesRodrigo Nalio Ramos, Céline Rodriguez, Margaux Hubert, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 2020
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapyAbhishek S Kashyap, Martina Schmittnaegel, Nicolò Rigamonti, et al.
Science Translational Medicine|June 17, 2021
Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan depositionStefan Bissinger, Carina Hage, Vinona Wagner, et al.
Nature Cell Biology|March 20, 2019
Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon responseCamilla Salvagno, Metamia Ciampricotti, Sander Tuit, et al.
Cell Reports|February 16, 2016
Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease ProgressionGiovanni Galletti, Cristina Scielzo, Federica Barbaglio, et al.
Science Translational Medicine|April 13, 2018
T cell-induced CSF1 promotes melanoma resistance to PD1 blockadeNatalie J Neubert, Martina Schmittnaegel, Natacha Bordry, et al.
Cancer Cell|September 14, 2016
T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic CellsIlaria Marigo, Serena Zilio, Giacomo Desantis, et al.
Cancer Cell|October 12, 2016
T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic CellsIlaria Marigo, Serena Zilio, Giacomo Desantis, et al.
European Journal of Cancer (Oxford, England : 1990)|November 8, 2020
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumourPhilippe A Cassier, Antoine Italiano, Carlos Gomez-Roca, et al.
Cancer Research|August 18, 2022
Efficacy of CD40 Agonists Is Mediated by Distinct cDC Subsets and Subverted by Suppressive MacrophagesAleksandar Murgaski, Máté Kiss, Helena Van Damme, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Clinical & Translational Immunology|February 22, 2020
CD163<sup>+</sup> tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytesRodrigo Nalio Ramos, Céline Rodriguez, Margaux Hubert, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 1, 2020
Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapyAbhishek S Kashyap, Martina Schmittnaegel, Nicolò Rigamonti, et al.
Science Translational Medicine|June 17, 2021
Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan depositionStefan Bissinger, Carina Hage, Vinona Wagner, et al.
Nature Cell Biology|March 20, 2019
Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon responseCamilla Salvagno, Metamia Ciampricotti, Sander Tuit, et al.
Cell Reports|February 16, 2016
Targeting Macrophages Sensitizes Chronic Lymphocytic Leukemia to Apoptosis and Inhibits Disease ProgressionGiovanni Galletti, Cristina Scielzo, Federica Barbaglio, et al.
Science Translational Medicine|April 13, 2018
T cell-induced CSF1 promotes melanoma resistance to PD1 blockadeNatalie J Neubert, Martina Schmittnaegel, Natacha Bordry, et al.
Cancer Cell|September 14, 2016
T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic CellsIlaria Marigo, Serena Zilio, Giacomo Desantis, et al.
Cancer Cell|October 12, 2016
T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic CellsIlaria Marigo, Serena Zilio, Giacomo Desantis, et al.
European Journal of Cancer (Oxford, England : 1990)|November 8, 2020
Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumourPhilippe A Cassier, Antoine Italiano, Carlos Gomez-Roca, et al.
Cancer Research|August 18, 2022
Efficacy of CD40 Agonists Is Mediated by Distinct cDC Subsets and Subverted by Suppressive MacrophagesAleksandar Murgaski, Máté Kiss, Helena Van Damme, et al.
Pageof 6